TB-500 (Thymosin Beta-4) Dosage in Preclinical Research: Protocols and Administration

Overview

TB-500 is a synthetic peptide fragment corresponding to the actin-binding domain of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid protein found in virtually all nucleated cells in the human body. Tβ4 is one of the most abundant intracellular peptides in mammals and plays a central role in actin sequestration, cell migration, and wound healing. This article reviews the dosing parameters and study designs reported in published preclinical research on Tβ4 and TB-500. All content is for research reference only.

Thymosin Beta-4 vs. TB-500: A Clarification

Thymosin Beta-4 (Tβ4) is the full 43-amino acid protein. TB-500 is a synthetic peptide corresponding to the Ac-SDKPDMAEIEKFDKSKLKKTE sequence (amino acids 17–23 of Tβ4), which is the region responsible for actin binding and many of the protein's biological activities. Most commercial TB-500 products contain this fragment rather than the full Tβ4 sequence. Published clinical trials have used full-length Tβ4, while most animal studies have used either the full protein or the active fragment.

Dose Ranges in Published Research

Animal studies on Tβ4 have used a wide range of doses depending on the model and administration route:

Wound healing models: Philp et al. (2010) reviewed multiple animal studies using topical Tβ4 at concentrations of 0.1–1 µg per wound site, demonstrating accelerated wound closure and reduced inflammation [1].

Cardiac injury models: Studies in rodent myocardial infarction models have used systemic doses of 150–1500 µg per animal (approximately 5–50 mg/kg in mice), administered intraperitoneally or intravenously [2].

Neurological models: Tβ4 doses of 6 mg/kg administered i.p. have been used in rodent stroke and traumatic brain injury models, with administration beginning within hours of injury [3].

Tendon and muscle repair: Studies have used 2–10 mg/kg subcutaneously or intraperitoneally in rodent tendon injury models.

Clinical Research (Tβ4)

Full-length Tβ4 has been studied in human clinical trials for specific indications. The RMTC (Racing Medication and Testing Consortium) bulletin documented a veterinary dosing regimen of 10 mg subcutaneously once weekly for six weeks, then monthly maintenance, for equine use [4]. Human trials for wound healing and dry eye syndrome have used topical formulations at concentrations of 0.03–0.1% [5].

Importantly, no clinical trials have been completed for TB-500 (the synthetic fragment) in humans. The available human data pertains to full-length Tβ4.

Administration Routes

- Subcutaneous injection: Most common route in animal studies and the veterinary dosing literature - Intraperitoneal injection: Used in rodent mechanistic studies - Intravenous infusion: Used in cardiac and neurological models - Topical application: Used in wound healing and dry eye studies

Reconstitution for Research Use

Lyophilized TB-500 is typically reconstituted in bacteriostatic water. For a 5 mg vial, adding 2.5 mL of bacteriostatic water yields a 2 mg/mL solution. The powder should be allowed to dissolve gently without vigorous shaking. Reconstituted peptide should be stored at 2–8°C and used within the manufacturer's recommended timeframe.

Important Note

All dosing information refers to parameters used in published preclinical and veterinary research. TB-500 is sold by Pure Pharm Peptides for research use only and is not intended for human or animal consumption.

For research use only. Not for human or animal consumption.

References

1. Philp, D., & Kleinman, H.K. (2010). Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Annals of the New York Academy of Sciences, 1194, 81–86.
2. Bock-Marquette, I., et al. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 432(7016), 466–472.
3. Morris, D.C., et al. (2010). Thymosin beta4 improves functional neurological outcome in a rat model of embolic stroke. Neuroscience, 169(2), 674–682.
4. RMTC. (2013). Thymosin β4 Bulletin, Version 2.0. Racing Medication and Testing Consortium.
5. Sosne, G., et al. (2010). Thymosin beta-4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Experimental Eye Research, 90(2), 243–248.